Antibody discovery and ADC development drive oncology innovation

The biotechnology sector is seeing significant advancements in antibody discovery and antibody-drug conjugate (ADC) development. Modern antibody platforms, such as Converge Bio, are shifting toward target-aware design and multiparameter optimization, focusing on delivering ranked candidates that balance binding affinity with developability and sequence constraints.

Simultaneously, the ADC market is experiencing rapid growth, with a valuation of approximately $14.75 billion in 2024 and projections to reach $36 billion by 2034. This growth is driven by the increasing complexity of oncology treatments. Successful ADC development requires specialized bioconjugation expertise to manage the three interdependent components: the antibody, the linker, and the cytotoxic payload. The linker, in particular, is critical for ensuring plasma stability and efficient payload release at target sites.